Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : NOTICE OF THE 2021 THIRD EXTRAORDINARY GENERAL MEETING

11/16/2021 | 04:36am EST

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

NOTICE OF THE 2021 THIRD EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2021 third extraordinary general meeting (the ''EGM'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') will be held at 1:30 p.m. on 7 December 2021 at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC for the purposes of considering and, if thought fit, passing (with or without modifications) the following resolutions. Unless otherwise indicated, capitalised terms used herein shall have the same meanings as defined in the circular of the Company dated 17 November 2021 (the ''Circular'').

SPECIAL RESOLUTION

1. To consider and approve the resolution on extension of authorisation valid period and change of authorised person for the Proposed Shanghai Henlius Listing.

ORDINARY RESOLUTIONS

2. To elect the executive Directors (by cumulative voting)(Note 5):

  1. Elect Mr. Wang Kexin as executive Director;
  2. Elect Ms. Guan Xiaohui as executive Director.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

17 November 2021

As at the date of this notice, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

- 1 -

Notes:

  1. A holder of H Shares entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote by poll instead of him. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number of H Shares in respect of which each such proxy is so appointed.
  2. In order to be valid, the form of proxy together with the power of attorney or other authority (if any) under which it is signed or a certified copy thereof, must be deposited at the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 24 hours before the time appointed for the holding of the EGM or any adjournment thereof. Return of the form of proxy will not preclude any holder of H Shares from attending the EGM and voting in person if such member so wishes and in such event, the form of proxy will be deemed to be revoked.
  3. For the purpose of determining the entitlement of H Shareholders to attend and vote at the EGM, the register of members of the Company for H Shares will be closed from Thursday, 2 December 2021 to Tuesday, 7 December 2021, both days inclusive. In order to qualify for attending and voting at the EGM, all transfer documents for H Shares together with the relevant share certificates should be lodged for registration with the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 4:30 p.m. on Wednesday, 1 December 2021.
  4. H Shareholders who attend the EGM in person or by proxy shall bear their own travelling and accommodation expenses.
  5. The cumulative voting system will be adopted for the election of executive Directors according to the Implementation Rules of Cumulative Voting System of the Company. For details of the cumulative voting system, please refer to the Articles of Association, the Implementation Rules of Cumulative Voting System of the Company and the proxy form despatched to the H Shareholders.
  6. This notice of EGM is despatched to the holders of H Shares only. The notice of EGM to the holders of A Shares and proxy form are separately published on the websites of the Company (http://www.fosunpharma.com) and of the Shanghai Stock Exchange (http://www.sse.com.cn).
  • for identification purposes only

- 2 -

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2021 09:35:04 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
04:40aCheap version of Merck COVID pill to be made for poorer nations
RE
01/19Fosun Pharma Unit Initiates Phase 3 Clinical Trial of Breast Cancer Treatment
MT
01/19Fosun Pharma Arm Starts Phase 3 Clinical Trial of Lung Cancer Treatment
MT
01/19SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
01/11Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and D..
AQ
01/11Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and ..
CI
01/07SHANGHAI FOSUN PHARMACEUTICAL : Entering into target fund lpa and possible continuing conn..
PU
01/06Chinese Regulators Accept Fosun Pharma Unit's Registration Application for Hemorrhage T..
MT
01/06SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
01/04SHANGHAI FOSUN PHARMACEUTICAL : List of directors and their roles and function(h sh..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 36 412 M 5 741 M 5 741 M
Net income 2021 4 454 M 702 M 702 M
Net Debt 2021 12 120 M 1 911 M 1 911 M
P/E ratio 2021 27,6x
Yield 2021 1,01%
Capitalization 112 B 17 674 M 17 682 M
EV / Sales 2021 3,41x
EV / Sales 2022 2,89x
Nbr of Employees 32 258
Free-Float 58,6%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 48,02 CNY
Average target price 65,43 CNY
Spread / Average Target 36,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Vice Chairman, Executive President & CEO
Yu Qing Chen Co-President
Ke Xin Wang Vice Chairman & Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman